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Abstract Tenascin-X (TN-X) is an extracellular matrix protein
whose absence results in an alteration of the mechanical
properties of connective tissue. To understand the mechanisms
of integration of TN-X in the extracellular matrix, overlay blot
assays were performed on skin extracts. A 100 kDa molecule
interacting with TN-X was identified by this method and this
interaction was abolished when the extract was digested by
chondroitinase. By solid-phase assays, we showed that dermatan
sulfate chains of decorin bind to the heparin-binding site included
within the fibronectin-type III domains 10 and 11 of TN-X. We
thus postulate that the association of TN-X with collagen fibrils
is mediated by decorin and contributes to the integrity of the
extracellular network. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Tenascin-X (TN-X) is an extracellular matrix molecule that
belongs to the tenascin family, comprising ¢ve members, i.e.
TN-C, TN-R, TN-X, and the more recently characterised TN-
Y and TN-W. All are multidomain proteins consisting of an
N-terminal region involved in oligomerisation, a series of epi-
dermal growth factor-like repeats, a variable number of ¢bro-
nectin-type III (FNIII) modules and one C-terminal domain
homologous to ¢brinogen (Fbg). This complex structure gives
rise to multiple interactions with proteins and carbohydrates
[1].
Some biological properties of TNs are mediated by their
binding to proteoglycans. Both extracellular and cell surface
proteoglycans have been shown to interact with TN-C. Perle-
can, a basement membrane heparan sulfate proteoglycan, in-
teracts with FNIII domains 3^5 of TN-C [2]. Some data sug-
gest that heparan sulfates present on the cell surface of
¢broblasts [3] or on hematopoietic cells [4] may be involved
in the interaction with the Fbg domain. Syndecan from em-
bryonic mesenchyme [5] and glypican [6], two heparan sulfate
receptors, have also been found to interact with TN-C using
their glycosaminoglycan (GAG) chains. Other proteoglycans
may interact via N-linked oligosaccharides (phosphacan/
RPTPj/L) or their core proteins (neurocan) [7^9].
Interaction of TN-X with extracellular proteoglycans has
not been demonstrated until now. This protein has the typical
arrangement of modules characteristic of TNs [10^13] and a
widespread expression during embryonic and adult life, where
it appears more speci¢cally in striated muscles, tendon and
ligament sheaths, dermis, adventitia of blood vessels, periph-
eral nerves and digestive tract [11,12,14^16]. By immunoelec-
tron microscopy, we have shown that TN-X is associated with
collagen ¢brils in the dermis and in the mesangium of kidney
glomeruli [14]. The major functions of TN-X are not clearly
understood at present, though some hypotheses have emerged
with the identi¢cation of one patient de¢cient in TN-X [17],
su¡ering from a connective tissue disorder known as Ehlers^
Danlos-like syndrome. Symptoms consist of skin and joint
hyperextensibility, vascular fragility and poor wound healing.
Ultrastructural analysis of the patient’s skin has shown a nor-
mal shape but reduced diameter of collagen ¢brils, the pres-
ence of electron dense elastin bodies beneath the dermal^epi-
dermal junction, an increased perivascular matrix and
abnormal packing of the myelin sheath laminae in cutaneous
nerves [17]. Considering these alterations of connective tissue
structure and biomechanical properties, TN-X might be in-
volved in extracellular matrix network formation.
The aim of our study was to identify extracellular matrix
molecules interacting with TN-X. As a screening procedure,
we performed overlay blotting experiments in which skin ex-
tracts were transferred to membranes and probed with re-
combinant proteins comprising FNIII domains 10 and 11 of
bovine TN-X. We have previously shown that such recombi-
nant proteins contain a heparin-binding site [18]. We have
found that decorin is a binding partner for TN-X and that
the dermatan sulfate GAG chains of this proteoglycan are
involved in the interaction.
2. Materials and methods
2.1. Proteins and antibodies
TN-X was extracted from bovine foetal skin and immunopuri¢ed
on a monoclonal antibody a⁄nity column using a previously de-
scribed procedure [14].
Polyclonal antibody against the FNX 9^10 recombinant protein
was raised by immunising guinea pigs. The antigen, a recombinant
protein corresponding to bovine FNIII domains 9 and 10, was pro-
duced in bacteria as previously described [19] and immunisation was
done at the Valbex Centre (Institut Universitaire de Technologie,
Universite¤ Claude Bernard, Lyon I, France). Immunoglobulins were
puri¢ed on protein G-Sepharose (Amersham/Pharmacia Biotech, Sa-
clay, France), following the manufacturer’s instructions.
Bovine skin decorin and cartilage biglycan were provided by B.
Font (IBCP, Lyon, France), who also provided us with the monoclo-
nal antibody (clone DS-I) speci¢c for the core protein of bovine
decorin. These reagents were given to our laboratory by H.U. Choi
and L.C. Rosenberg (Monte¢ore Medical Center, New York, USA)
[20]. Bovine type XIV collagen was a generous gift from E. Aubert-
Foucher (IBCP, Lyon, France).
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2.2. Preparation of tissue extracts
Bovine foetal tissues were powdered in a freezer mill (SPEX indus-
tries, Metuchen, NJ, USA). The powder was suspended in extraction
bu¡er composed of 0.5 M NaCl diluted in phosphate-bu¡ered saline
(PBS), in the presence of a mixture of protease inhibitors (1 mM
phenylmethylsulfonyl £uoride, 2 mM EGTA, 2 mM EDTA and 10
mM N-ethyl maleimide). The extraction was continued for 5 h at 4‡C.
After centrifugation (15 min at 20 000Ug), the supernatant was col-
lected and stored at 320‡C.
2.3. Chondroitinase digestions
Prior to digestion, tissue extracts or puri¢ed proteoglycans were
dialysed against 50 mM Tris^HCl, 60 mM sodium acetate, pH 8.0,
2 mM EDTA, and were then digested for 2 h at 37‡C with 25 mU of
chondroitinase ABC (chondroitin ABC lyase (EC 4.2.2.4) from Pro-
teus vulgaris, Boehringer Mannheim, Meylan, France).
2.4. Overlay blot experiments
Binding of TN-X recombinant fragments to molecules transferred
to membranes was performed according to the method of Font et al.
[21]. Tissue extracts or puri¢ed proteoglycans were loaded on polyac-
rylamide gels and transferred to PDVF membranes (Immobilon,
Millipore, Saint-Quentin-en-Yvelines, France) using standard proce-
dures [14]. The membrane was saturated for 2 h at room temperature
with 1% bovine serum albumin (BSA) diluted in PBS. Then, incuba-
tion with soluble recombinant TN-X fragments (5 Wg/ml, diluted in
PBS^BSA) was carried out overnight at 4‡C. Control membranes
were incubated with PBS^BSA. Bound recombinant protein was de-
tected by successive incubations in polyclonal antibody against FNX
9^10 and peroxidase-conjugated anti-guinea pig IgG (Biosys, Com-
pie'gne, France). Further development was performed using a chem-
iluminescence kit (NEN Life Science, Paris, France).
2.5. Solid-phase assays
Ninety-six well microtiter plates (Maxisorp, Nunc) were coated
overnight at 4‡C with proteins diluted in PBS. All further steps
were done at room temperature. Wells were saturated with T-PBS^
BSA for 2 h and then incubated with puri¢ed decorin for a further 2 h.
Wells were rinsed with PBS, incubated for 1 h with monoclonal anti-
body speci¢c for decorin (ascites £uid diluted 1/1000) and then for 30
min with anti-mouse IgG conjugated to peroxidase (Biosys). After a
¢nal set of rinses, bound peroxidase was detected with H2O2 and 2,2-
azino-bis(3-ethylbenthiazoline-6-sulfonic acid) and the absorbance
read at 405 nm. Each data point is the mean of triplicate determina-
tions and bars represent the standard error of the mean.
For inhibition experiments, incubation with GAGs was performed
for 30 min before addition of decorin and visualisation of bound
decorin was performed as described above.
3. Results
As the ¢rst approach to identifying extracellular ligands of
TN-X, we performed overlay blot experiments on skin ex-
tracts. The blots were probed with a recombinant protein
comprising FNIII domains 10 and 11 of bovine TN-X. This
protein was tested because we have previously demonstrated
that this region is responsible for heparin-binding activity and
is able to bind cell surface heparan sulfates [18]. We postu-
lated that extracellular matrix proteoglycans may also bind to
TN-X via this region. In Fig. 1, we can observe that in the
blots incubated with FNX 10^11 protein, a fuzzy band of
approximately 100 kDa was revealed. This band was not
found in the control blot incubated with BSA. The high mo-
lecular mass bands that appeared in all blots represent the
TN-X present in the extract, which is recognised by the poly-
clonal antibody against FNX 9^10. After chondroitinase di-
gestion of the extract, the 100 kDa band was no longer
present. These results indicate that a 100 kDa proteoglycan
from skin interacts with the FNX 10^11 protein and that the
GAG chains are crucial for this interaction. Two candidate
proteoglycans having this molecular mass, namely biglycan
and decorin [22], were tested using the same overlay assay.
The results, shown in Fig. 2, clearly demonstrate that puri¢ed
Fig. 1. Interaction of recombinant FNX 10^11 protein with bovine
skin extracts by overlay blotting experiments. Bovine skin extracts
were loaded on a 10% acrylamide gel and transferred to a PVDF
membrane. Lanes 1 and 2: untreated skin extract; lane 3: chondroi-
tinase-digested skin extract. Membrane corresponding to lane 1 was
incubated with BSA and lanes 2 and 3 were incubated with re-
combinant FNX 10^11 protein. Visualisation of the bound protein
was performed as described in Section 2.
Fig. 2. Interaction of recombinant FNX 10^11 protein with puri¢ed
biglycan and decorin. Puri¢ed biglycan (B), decorin (D) or skin ex-
tract (S) were resolved on 4^15% acrylamide gels and transferred to
PVDF. Lanes 1^4: overlay blot incubated with BSA (lanes 1 and 2)
or with FNX 10^11 (lanes 3 and 4) and revealed as described
above. Lanes 5^7: Western blot revealed with monoclonal antibody
against decorin. Lanes 1^7: no enzymatic treatment; lane 7: chon-
droitinase digestion.
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decorin interacted with the FNX 10^11 protein, whereas bi-
glycan did not. Also, in this experiment digestion by chon-
droitinase abolished the binding. The integrity of the core
protein of decorin after this treatment was veri¢ed by an
immunoblotting using the anti-decorin monoclonal antibody.
A single band migrating at 40^48 kDa was revealed (Fig. 2),
which was consistent with the molecular characteristics of
decorin [22]. On this immunoblot, we also veri¢ed that the
migration of undigested decorin in the skin extract was in the
same position as the band revealed on the overlay blot with
FNX 10^11.
Further characterisation of this interaction between decorin
and TN-X was performed by solid-phase assays. The interac-
tion also occurred when FNX 10^11 was used as the immo-
bilised substrate with decorin in the soluble phase. As shown
in Fig. 3, interaction was dose-dependent and saturable. In the
previous study, dealing with the heparin-binding site, we dem-
onstrated that it was conformational and involved both do-
mains 10 and 11. For the interaction with decorin, a similar
situation was observed; in Fig. 4, the results clearly indicate
that both domains 10 and 11 must be present to obtain an
interaction. By solid-phase assays, we also showed that the
whole TN-X molecule, puri¢ed from skin, was able to interact
with decorin (Fig. 4). Finally, we attempted to identify the
GAG chains of the proteoglycan decorin that were responsi-
ble for interaction with TN-X. The results are given in Fig. 5.
Chondroitinase digestion of decorin resulted in a strong inhi-
bition of the interaction. Competition with soluble GAG
chains had a similar inhibitory e¡ect whether heparin, hepar-
an or dermatan sulfate were used; in contrast, no inhibition
was observed when incubating with chondroitin sulfate
chains.
4. Discussion
In this study, we have been able to identify decorin as a
ligand for TN-X. The site of interaction is closely related or
similar to the heparin-binding site that we have previously
characterised. This site is conformational, located at the inter-
face between FNIII domains 10 and 11 of bovine TN-X, as
determined using recombinant proteins, and is e¡ective in the
whole TN-X protein [18]. Using the same set of recombinant
proteins, we performed ligand blotting experiments and de-
tected an interaction with decorin. Using solid-phase assays,
we observed that interaction with decorin has the same re-
quirements as heparin-binding, i.e. the individual domains
10 or 11 do not interact while proteins bearing contiguous
domains 10 and 11 (FNX 10^11 and FNX 9^10^11) do and
the interaction is inhibited by soluble GAG heparin but not
by chondroitin sulfate. Digestion of decorin with chondroiti-
nase ABC abolished the interaction. Taken together, these
results suggest that the heparin-binding site of domains 10
and 11 of TN-X is responsible for binding to decorin.
Competition experiments performed with GAGs demon-
strate that heparin, heparan sulfate and dermatan sulfate
have a strong inhibitory e¡ect whereas chondroitin sulfate is
ine¡ective. This inhibition pro¢le suggests that the presence of
iduronate-rich domains, present in heparin, heparan sulfate
and dermatan sulfate but absent in chondroitin sulfate, may
be important for this interaction. A similar pattern of inter-
action has been described for heparin cofactor II [23] and
Fig. 3. Solid-phase assay of the interaction between FNX 10^11 and
puri¢ed decorin. Wells were coated with 0.5 Wg FNX 10^11 per
well. After saturation with BSA, various amounts of decorin were
added. Bound decorin was detected by monoclonal antibody.
Fig. 4. Interaction of TN-X and FNX domains with decorin by sol-
id-phase assays. Wells were coated with 3 Wg TN-X, 1 Wg collagen
XIV (positive control) or 1 Wg per well of FNX 10, FNX 11 or
FNX 10^11 recombinant proteins. Interaction was performed with
1 Wg decorin per well and visualisation was done as described in
Section 2.
Fig. 5. In£uence of GAG chains on the interaction between FNX
10^11 and decorin. Wells were coated with 1 Wg of recombinant
FNX 10^11 protein. After saturation with BSA, soluble GAG
chains were added at 10 Wg per well. Further incubation with decor-
in and visualisation were done as described above.
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hepatocyte growth factor/scatter factor [24], both of which are
able to bind both heparan and dermatan sulfates.
In a previous study we showed, by immunoelectron micros-
copy, that TN-X is located around collagen ¢brils in dermis
[14]. Since decorin is known to interact with ¢brillar collagens
via its core protein [25], we propose that this small proteogly-
can may act as a link between collagen ¢brils and TN-X in
tissues. This hypothesis is corroborated by the observation of
an alteration of skin tensile strength in the absence of decorin
in knock-out mice [26] or in the absence of TN-X in a patient
su¡ering from Ehlers^Danlos syndrome [17]. This property of
TN-X to interact with decorin may also interfere with some
functions of decorin that are due to GAG chains, such as
maintenance of inter¢brillar spacing [27], interaction with ¢-
bril-associated type XII and XIV collagens [21,28] or interac-
tion with heparin cofactor II [29]. In conclusion, the interac-
tion between TN-X and decorin demonstrated in this paper
might have important biological implications in terms of
building extracellular networks leading to the mechanical
properties of connective tissues in normal and pathological
situations.
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